Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Maluf FC, Pereira FMT, Silva AG, et al. Consensus on the treatment and follow-up for metastatic castration-resistant prostate cancer: a report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7(7):559–571.
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972 Jul;22(4):232–240.
   PubMedGoogle Scholar
• Chatalic KL, Heskamp S, Konijnenberg M, et al. Towards personalized treatment of prostate cancer: pSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016;6(6):849–861. DOI:10.7150/thno.14744
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009 Feb;6(2):76–85.
   PubMedGoogle Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):467–479.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016 Aug;70(2):256–262.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015 Mar;67(3):470–479.
   PubMed Web of Science ®Google Scholar
• Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015 Mar;9(3–4):90–96.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020 Nov 10;38(32):3763–3772.
   PubMed Web of Science ®Google Scholar
• Keisner SV. Rucaparib and olaparib for the treatment of prostate cancer: a clinician’s guide to choice of therapy. J Oncol Pharm Pract. 2022 Apr 19;28(7):10781552221094308.
   Web of Science ®Google Scholar
• Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019 Jan;75(1):88–99.
   PubMed Web of Science ®Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021 Sep 16;385(12):1091–1103.
   PubMed Web of Science ®Google Scholar
• Dong L, Zieren RC, Xue W, et al. Metastatic prostate cancer remains incurable, why? Asian J Urol. 2019 Jan;6(1):26–41.
   PubMed Web of Science ®Google Scholar
• Altiparmak Gulec B, Yurt F. Treatment with radiopharmaceuticals and radionuclides in breast cancer: current options. Eur J Breast Health. 2021 Jul;17(3):214–219.
   PubMed Web of Science ®Google Scholar
• Jadvar H. Targeted alpha-therapy in cancer management: synopsis of preclinical and clinical studies. Cancer Biother Radiopharm. 2020 Sep;35(7):475–484.
   PubMed Web of Science ®Google Scholar
• Yeong CH, Cheng MH, Ng KH. Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B. 2014 Oct;15(10):845–863.
   PubMed Web of Science ®Google Scholar
• Tafreshi NK, Doligalski ML, Tichacek CJ, et al. Development of targeted alpha particle therapy for solid tumors. Molecules. 2019 Nov 26;24(23):4314.
   PubMed Web of Science ®Google Scholar
• Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518–525.
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014 May;41(5):925–933.
   PubMed Web of Science ®Google Scholar
• Das S, Al-Toubah T, El-Haddad G, et al. (177)lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1023–1031.
   PubMed Web of Science ®Google Scholar
• Emmett L, Willowson K, Violet J, et al. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017 Mar;64(1):52–60.
   PubMed Web of Science ®Google Scholar
• Sgouros G, Bodei L, McDevitt MR, et al. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589–608.
   PubMed Web of Science ®Google Scholar
• Hennrich U, Eder M. [(177)lu]lu-PSMA-617(Pluvicto(TM)): the first FDA-Approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292.
   PubMedGoogle Scholar
• Jia AK, Zaorsky NG, Spratt DE, et al. Lutetium-177 DOTATATE: a practical review. Pract Radiat Oncol. 2022;12(4):305–311.
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017 Jan 12;376(2):125–135.
   PubMed Web of Science ®Google Scholar
• Stokke C, Kvassheim M, Blakkisrud J. Radionuclides for targeted therapy: physical properties. Molecules. 2022 Aug 25;27(17):5429.
   PubMed Web of Science ®Google Scholar
• Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot. 2005 May;62(5):667–679.
   PubMed Web of Science ®Google Scholar
• Ma J, Li L, Liao T, et al. Efficacy and safety of (225)Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:796657.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113–122.
   PubMed Web of Science ®Google Scholar
• Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014 Oct;28(4):555–563.
   PubMed Web of Science ®Google Scholar
• Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623.
   PubMed Web of Science ®Google Scholar
• Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998 Oct;52(4):637–640.
   PubMed Web of Science ®Google Scholar
• Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005 May;288(5):C975–81.
   PubMed Web of Science ®Google Scholar
• Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995 Sep 4;62(5):552–558.
   PubMed Web of Science ®Google Scholar
• Wright GL Jr., Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995 Jan;1(1):18–28.
   PubMedGoogle Scholar
• Parsi M, Desai MH, Desai D, et al. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol. 2021 Jun 28;38(8):89.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Violet J, Hicks RJ, et al. [(177)lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun;19(6):825–833.
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997 Jan;3(1):81–85.
   PubMed Web of Science ®Google Scholar
• Tolkach Y, Gevensleben H, Bundschuh R, et al. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018 Jun;169(3):447–455.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Rahbar K, Essler M, et al. PSMA-Based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients. Semin Nucl Med. 2020 Jan;50(1):98–109.
   PubMed Web of Science ®Google Scholar
• Whiting P, Savovic J, Higgins JP, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016 Jan;69:225–234.
   PubMed Web of Science ®Google Scholar
• Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016 Jul;41(7):522–528.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-Targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016 Aug;57(8):1170–1176.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015 Dec;5(1):114.
   PubMedGoogle Scholar
• Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016 Sep;57(9):1334–1338.
   PubMed Web of Science ®Google Scholar
• Brauer A, Grubert LS, Roll W, et al. (177)lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663–1670.
   PubMed Web of Science ®Google Scholar
• Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017 Jan;58(1):85–90.
   PubMed Web of Science ®Google Scholar
• Zarehparvar Moghadam S, Askari E, Divband G, et al. Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with (177)Lu-PSMA-617: a single center study. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Jul;41(4):239–246.
   PubMed Web of Science ®Google Scholar
• Kemppainen J, Kangasmaki A, Malaspina S, et al. Single center experience with a 4-week (177)Lu-PSMA-617 treatment interval in patients with metastatic castration-resistant prostate cancer. Cancers (Basel). 2022 Dec 14;14(24):6155.
   PubMed Web of Science ®Google Scholar
• Rahbar K, Boegemann M, Yordanova A, et al. PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12–19.
   PubMed Web of Science ®Google Scholar
• Mirshahvalad SA, Farzanefar S, Abbasi M. Therapeutic outcomes of (177)Lu-PSMA targeted therapy in patients with metastatic castration-resistant prostate cancer: a single-center study. Asia Ocean J Nucl Med Biol. 2023;11(1):23–29.
   PubMedGoogle Scholar
• Schneider CA, Tager P, Hammes J, et al. Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. Nuklearmedizin. 2022 Feb;61(1):25–32.
   PubMedGoogle Scholar
• Soydal C, Araz M, Urun Y, et al. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. Q J Nucl Med Mol Imaging. 2021 Sep;65(3):282–286.
   PubMed Web of Science ®Google Scholar
• Leibowitz R, Davidson T, Gadot M, et al. A retrospective analysis of the safety and activity of lutetium-177-prostate-specific membrane antigen radionuclide treatment in older patients with metastatic castration-resistant prostate cancer. Oncology. 2020 Sep;25(9):787–792.
   Google Scholar
• Tatkovic A, McBean R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2021 Oct;65(6):740–747.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Wegen S, Yordanova A, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448–1454.
   PubMed Web of Science ®Google Scholar
• Mader N, Groener D, Tselis N, et al. Outcome of (177)Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer. Cancers (Basel). 2021 Aug 20;13(16):4193.
   PubMed Web of Science ®Google Scholar
• Khreish F, Ghazal Z, Marlowe RJ, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1075–1085.
   PubMed Web of Science ®Google Scholar
• Meyrick D, Gallyamov M, Sabarimurugan S, et al. Real-world data analysis of efficacy and survival after lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer. Target Oncol. 2021 May;16(3):369–380.
   PubMed Web of Science ®Google Scholar
• Assadi M, Rezaei S, Jafari E, et al. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: initial clinical experience after 2 years. World J Nucl Med. 2020 Jan;19(1):15–20.
   PubMedGoogle Scholar
• Yadav MP, Ballal S, Tripathi M, et al. (177)lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):81–91.
   PubMed Web of Science ®Google Scholar
• Emmett L, Crumbaker M, Ho B, et al. Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019 Feb;17(1):15–22.
   PubMed Web of Science ®Google Scholar
• Satapathy S, Mittal BR, Sood A, et al. (177)lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1754–1764.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, et al. [(177)lu]lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 27;397(10276):797–804.
   PubMed Web of Science ®Google Scholar
• McBean R, O’Kane B, Parsons R, et al. Lu177-PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2019 Aug;63(4):538–545.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Sansovini M, Severi S, et al. Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. Br J Cancer. 2021 Oct;125(9):1226–1232.
   PubMed Web of Science ®Google Scholar
• Baum RP, Kulkarni HR, Schuchardt C, et al. 177lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016 Jul;57(7):1006–1013.
   PubMed Web of Science ®Google Scholar
• Aghdam RA, Amoui M, Ghodsirad M, et al. Efficacy and safety of (177)Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: first experience in West Asia - a prospective study. World J Nucl Med. 2019 Jul;18(3):258–265.
   PubMedGoogle Scholar
• FDA D.I.S.C.O Burst Edition: fDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy US food & drug administration. 2022.
   Google Scholar
• Vaishampayan N, Morris MJ, Krause BJ, et al. [177lu]lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: prior and concomitant treatment subgroup analyses of the VISION trial. J Clin Oncol. 2022;40(16_suppl):5001. DOI:10.1200/JCO.2022.40.16_suppl.5001
   Google Scholar
• LLC CU. A multi-center, open-label, randomized phase 3 trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. [ Updated 2023 Feb 10]. Accessed Feb 11, 2023. ClinicalTrialsgov identifier: NCT05204927 https://clinicaltrialsgov/ct2/show/NCT05204927.
   Google Scholar
• Pharmaceuticals N Psmafore: a phase III, open-label, multi-center, randomized study comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the treatment of taxane naïve men with progressive metastatic castrate resistant prostate cancer. [ Updated 2023 Mar 3]. Accessed Mar 7, 2023. ClinicalTrialsgov Identifier: NCT04689828 https://wwwclinicaltrialsgov/ct2/show/study/NCT04689828.
   Google Scholar
• Emmett L, Subramaniam S, Joshua AM, et al. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021 Nov;128(5):642–651.
   PubMed Web of Science ®Google Scholar
• Centre PMC. Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer. [ Updated 2022 Jul 22]. Accessed Feb 8, 2023. ClinicalTrialsgov Identifier: NCT05340374 https://clinicaltrialsgov/ct2/show/NCT05340374.
   Google Scholar
• Centre PMC 177lu-PSMA-617 therapy and olaparib in patients with metastatic castration resistant prostate cancer. [ Updated 2022 Nov 17]. Accessed Feb 8, 2023. ClinicalTrialsgov Identifier: NCT03874884 https://clinicaltrialsgov/ct2/show/NCT03874884.
   Google Scholar
• Kostos L, Buteau JP, Yeung T, et al. AlphaBet: combination of radium-223 and [(17) (7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med. 2022;9:1059122.
   PubMed Web of Science ®Google Scholar
• Koshkin V Phase I/II study of CDK4/6 Inhibition with abemaciclib to upregulate PSMA expression prior to 177Lu-PSMA-617 treatment in patients with metastatic castrate resistant prostate cancer (mcrpc) previously treated with novel hormonal agents and chemotherapy. ClinicalTrialsgov identifier: NCT05113537 https://clinicaltrialsgov/ct2/show/NCT05113537.
   Google Scholar
• Utah Uo. A phase ib dose-escalation study of cabozantinib in combination with lutetium-177 (177Lu)-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). [ Updated 2022 Nov 16]. Accessed Feb 8, 2023. ClinicalTrialsgov identifier: NCT05613894 https://clinicaltrialsgov/ct2/show/NCT05613894.
   Google Scholar
• Aggarwal R Immunogenic priming with PSMA-Targeted radioligand therapy in advanced prostate cancer: a phase 1b study of 177Lu-PSMA-617 in combination with pembrolizumab. [ Updated 2022 Apr 19]. AccessedFeb 8, 2023. ClinicalTrialsgov identifier: NCT03805594 https://clinicaltrialsgov/ct2/show/NCT03805594.
   Google Scholar
• Centre PMC. Phase Ib/II study of Radionuclide 177Lutetium-PSMA-617 therapy in combination with pembrolizumab for treatment of metastatic Castration Resistant Prostate Cancer (mCRPC). [ Updated 2022 May 25]. Accessed Feb 8, 2023. ClinicalTrialsgov identifier: NCT03658447 https://clinicaltrialsgov/ct2/show/NCT03658447.
   Google Scholar
• Group AaNZUaPCT. Phase II study of Radionuclide 177Lu-PSMA therapy versus 177Lu-PSMA in combination with ipilimumab and nivolumab for men with metastatic castration resistant prostate cancer (mCRPC). [ Updated 2022 Jun 10]. Accessed Feb 8, 2023. ClinicalTrialsgov Identifier: NCT05150236 https://clinicaltrialsgov/ct2/show/NCT05150236.
   Google Scholar
• NIH U.S. National Library of Medicine- ClinicalTrials.Gov. Accessed Jun 22, 2022. https://clinicaltrials.gov/ct2/results?cond=Prostate+Cancer&term=Lu177-PSMA&cntry=&state=&city=&dist=.
   Google Scholar
• Marinova M, Alamdar R, Ahmadzadehfar H, et al. Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. Nuklearmedizin. 2020 Dec;59(6):409–414.
   PubMedGoogle Scholar
• Zang J, Fan X, Wang H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148–158.
   PubMed Web of Science ®Google Scholar
• Zang J, Liu Q, Sui H, et al. (177)lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020 Dec;61(12):1772–1778.
   PubMed Web of Science ®Google Scholar
• Plichta KA, Graves SA, Buatti JM. Prostate-Specific Membrane Antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer. Int J Mol Sci. 2021 Nov 9;22(22):12095.
   PubMed Web of Science ®Google Scholar
• Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 Nov;23(11):1389–1397.
   PubMed Web of Science ®Google Scholar
• Suman S, Parghane RV, Joshi A, et al. Therapeutic efficacy, prognostic variables and clinical outcome of (177)Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort. Br J Radiol. 2019 Dec;92(1104):20190380.
   PubMed Web of Science ®Google Scholar
• Pathmanandavel S, Crumbaker M, Ho B, et al. Evaluation of (177)Lu-PSMA-617 SPECT/CT quantitation as a response biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2023 Feb;64(2):221–226.
   PubMed Web of Science ®Google Scholar
• Ferdinandus J, Violet J, Sandhu S, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2322–2327.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Massard C, Smith M, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015 Jul;68(1):42–50.
   PubMed Web of Science ®Google Scholar
• Ferdinandus J, Eppard E, Gaertner FC, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017 Feb;58(2):312–319.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Schlolaut S, Fimmers R, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017 Nov 28;8(61):103108–103116.
   PubMedGoogle Scholar
• Wrenger R, Juptner M, Marx M, et al. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy. BMC Urol. 2022 Jul 4;22(1):96.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nagata M, Lu Y, et al. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS ONE. 2020;15(1):e0226219. DOI:10.1371/journal.pone.0226219
   PubMed Web of Science ®Google Scholar
• Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019 Oct;76(4):469–478.
   PubMed Web of Science ®Google Scholar
• Kuo PH, Rahbar K, Hesterman J, et al. [68ga]ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy. ASCO Annual Meeting. 2022;40(16):5002. DOI:10.1200/JCO.2022.40.16_suppl.5002
   Google Scholar
• Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 Aug;22(8):1115–1125.
   PubMed Web of Science ®Google Scholar
• Sun M, Niaz MO, Nelson A, et al. Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Cureus. 2020 Jun 30;12(6):e8921.
   PubMed Web of Science ®Google Scholar
• Stuparu AD, Capri JR, Meyer CAL, et al. Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med. 2021 Jul 1;62(7):989–995.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Giesel FL, Heussel CP, et al. Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020 May;61(5):683–688.
   PubMed Web of Science ®Google Scholar
• Yadav MP, Ballal S, Sahoo RK, et al. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients. PLoS ONE. 2021;16(5):e0251375. DOI:10.1371/journal.pone.0251375
   PubMed Web of Science ®Google Scholar
• Biospace. Janux therapeutics announces FDA clearance of investigational new drug application for JANX007 Ap-TfMC-RPCM, 2022. Accessed Feb, 2023. https://www.biospace.com/article/releases/janux-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-janx007-a-psma-tractr-for-metastatic-castration-resistant-prostate-cancer/.
   Google Scholar